The advent of highly effective disease modifying therapy has transformed the landscape of
multiple sclerosis (MS) care over the last two decades. However, there remains a critical …

The autoimmune diseases of the central nervous system (CNS) represent individual
heterogeneity with different disease entities. Although clinical and imaging features make it …

Introduction: Multiple Sclerosis (MS) is the most common immune-mediated chronic
neurodegenerative disease of the central nervous system (CNS) affecting young people …

Blood-based biomarkers can be economic and easily accessible tools for monitoring and
predicting disease activity in multiple sclerosis. The objective of this study was to determine …

Introduction Circulating microRNAs are promising biomarkers for multiple sclerosis (MS).
Our aim was to correlate serum microRNA levels with various magnetic resonance imaging …

Background and Objectives To evaluate CSF inflammatory markers with accumulation of
cortical damage as well as disease activity in patients with early relapsing-remitting MS …

Cognitive Impairment (CI) is one of the most common and devastating manifestations in
patients with Multiple Sclerosis (MS), which directly impacts the quality of life (QOL) and …

Background: Blood–barrier (BBB) breakdown and active inflammation are hallmarks of
relapsing multiple sclerosis (RMS), but the molecular events contributing to the development …

Osteopontin (OPN) is a multifunctional matrix glycoprotein with neuroprotective and
immunomodulatory properties. This study explored the potential of OPN-loaded acellular …

In progressive multiple sclerosis (MS), compartmentalized inflammation contributes to the
complex pathology of tissue damage. However, the interplay of epigenetic regulation and …